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Background: Celecoxib, a selective inhibitor of cyclooxygenase-2, can directly modulate many voltage-activated
potassium, sodium and calcium channels and alter functioning of excitable cells. The inhibitory and facilitating
effects of celecoxib on ion channels occur at low micromolar concentrations, bordering on therapeutic concentrations
achievable in the clinical setting. The experiments described here were performed with the goals (1) to increase the
range of ion channels tested, and (2) to examine possible differences in celecoxib’s effects on channels from different
species.
Findings: The channels examined in this study using patch-clamp and intracellular recording methods were human
KV1.3 channels expressed in CHO cells, L-type Ca
2+ channels (LTCC) from guinea pig cardiomyocytes, and LTCCs from
Drosophila larval body-wall muscles. Celecoxib inhibited KV1.3 currents with IC50 of 5.0 μM at the end of 200 ms pulses
to +20 mV. Celecoxib inhibited peak currents through guinea pig and Drosophila LTCCs with IC50s of 10.6 and 76.0 μM,
respectively.
Conclusions: As blockade of KV1.3 channels is associated with suppression of inflammatory immune reactions, the
finding that celecoxib can inhibit these channels raises a question of possible contribution of KV1.3 inhibition to the
anti-inflammatory effects of celecoxib. On the other hand, the Ca2+ channel results are consistent with previous
observations indicating that, in contrast to K+ channels, strength of celecoxib effects on LTCCs strongly varies from
species to species.
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Numerous studies have shown that celecoxib, a highly
popular inhibitor of cyclooxygenase-2 (COX-2), can dir-
ectly interact with many molecular targets unrelated to
COX-2, including ion channels. Celecoxib inhibits
NaV1.5 [1] (and other voltage-activated Na
+ channels
[2,3]), L-type Ca2+ channels (LTCC) [4,5], T-type Ca2+
channels [6], KV1.5 [7], KV2.1 [7,8] (and also Drosophila
KV2 [9,10]), KV4.3 [1,7], KV7.1 [1,7,11], KV11.1 [1], while
stimulating KV7.2-5 channels [5,11,12] at low micromo-
lar concentrations independently of cyclooxygenase in-
hibition. Substantial and sometimes dramatic changes in
cellular and tissue physiology following modulation of
ion channel function by celecoxib have been also de-
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unless otherwise stated.The experiments described in this report were per-
formed with the aims (1) to increase the number of ion
channels tested with celecoxib, and (2) to examine pos-
sible differences in celecoxib’s effects on homologous ion
channels from different experimental systems. These
goals address the need to conduct a comprehensive re-
search of celecoxib actions on ion channels, including
drug testing in different experimental systems, as differ-
ences between human and animal cardiac excitability
usually do not allow reliable conclusions on the basis of
a few animal studies.
Experimental procedures
Patch-clamp
Experiments involving measurements of KV1.3 channels
stably expressed in CHO cells and L-type Ca2+ channels
in guinea pig ventricular myocytes were performed by
Dr. David Rampe (Aventis Pharmaceuticals). Experimen-
tal procedures and protocols were approved by thentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Committee (Bridgewater, NJ) and conform to the Guide
for the Care and Use of Laboratory Animals published
by the National Institutes of Health. Single ventricular
myocytes were isolated from guinea pigs as described
previously [14]. Briefly, currents were recorded using an
Axopatch 200B amplifier (Axon Instruments, CA, USA).
Electrodes for whole-cell recordings (1–4 MΩ resist-
ance) were made from TW150F glass capillary tubes
(WPI, Sarasota, FL). For KV1.3 channel recordings, the
electrode solution contained (in mM): potassium as-
partate (120), KCl (20), disodium adenosine triphos-
phate (4), HEPES (5), and MgCl2 (1), pH 7.2 with
KOH. The external solution contained: NaCl (130),
KCl (5), sodium acetate (2.8), MgCl2 (1), HEPES (10),
glucose (10), CaCl2 (1), pH 7.4 with NaOH. For Ca
2+
channel recordings, the electrode solution contained:
cesium methanesulfonate (130), tetraethylammonium
chloride (20), MgCl2 (1), EGTA (10), HEPES (10), Tris-
ATP (4), Tris-GTP (0.3), phosphocreatine (14), 50 U/
ml creatine phosphokinase, pH 7.2 with CsOH. The
bath solution contained: NaCl (137), CsCl (5.4), CaCl2
(1.8), MgCl2 (1), HEPES (10), glucose (10), pH 7.4 with
NaOH.
Intracellular recordings
L-type currents were recorded using the two-
microelectrode voltage-clamp technique from larval
ventral longitudinal muscle 12 as described previously
[15]. Electrodes were pulled from thin-walled borosili-
cate glass capillaries (World Precision Instruments,
Sarasota, FL) using a Sutter Instruments puller, model
P-97. Electrodes for potential measurements were
filled with 2.5 M KCl, while current passing electrodes
were filled with a 3:1 mixture of 2.5 M KCl and 2 M
potassium citrate. Resistance of electrodes was be-
tween 8 and 14 MΩ. Holding potential of–40 mV was
used to inactivate T-type Ca2+ channels [16]. Recor-
ding saline contained (in mM): NaCl (77.5), KCl
(5.0), MgCl2 (4), NaHCO3 (2.5), trehalose (5.0), su-
crose (115.0), HEPES (5.0), tetraethylammonium
(TEA) (20.0), 4-aminopyridine (4-AP) (1.0), quinidine
(0.1), and BaCl2 (10.0), pH 7.1 with NaOH. Voltage-
activated potassium currents were blocked by TEA,
quinidine, and 4-AP. Barium was used as charge car-
rier to reduce muscle contractions, to further inhibit
K+ channels, and to eliminate Ca2+-dependent inacti-
vation of LTCCs. To reduce the run-down error, only a
single run of the experimental protocol was used to
record from each muscle fiber.
All experiments were performed at room temperature.
All values are means ± s.e.m; (n) indicates the number of
experiments. Statistical analysis was performed by un-
paired t-test; P < 0.05 was considered significant.Effects of celecoxib on KV1.3 channels
Delayed rectifier KV1.3 channels are found in T and B
lymphocytes where they regulate membrane potential
and calcium signaling [17,18]. KV1.3 channels are phys-
ically coupled to the T-cell receptor signaling complex
through a series of adaptor proteins and play an essential
role in T-cell proliferation and activation [19-23]. Block-
ade of KV1.3 channels in effector-memory T-cells sup-
presses calcium signaling, cytokine production and cell
proliferation [20,21,23]. In vivo, KV1.3 blockers paralyze
effector-memory T-cells at sites of inflammation and
prevent their reactivation in inflamed tissues. Modula-
tion of KV1.3 channels may be one of many mechanisms
that contribute to apoptosis [24,25].
In this study, effects of celecoxib on human KV1.3 chan-
nels expressed in CHO cells were examined using patch-
clamp method. Figure 1A,C shows that celecoxib can
inhibit whole-cell KV1.3 currents with an IC50 of 5.0 μM
(for the currents at the end of 200 ms pulses). Note that
celecoxib accelerated inactivation of the current, which in-
dicates that the drug effect may be stronger during longer
depolarizations.
Since blockade of KV1.3 channels is associated with
suppression of inflammatory immune and autoimmune
reactions, these findings raise a question about possible
contribution of KV1.3 inhibition into the anti-inflammatory
action of celecoxib, making a strong case for further re-
search in this direction.
Effects of celecoxib on LTCCs in Drosophila and guinea
pig
We assessed effects of celecoxib on L-type Ca2+ channels
in two model systems, guinea pig ventricular myocytes
and Drosophila larval body-wall muscles. The rationale
behind this test was two-fold. Firstly, although two re-
ports have previously addressed inhibition of L-type Ca2+
channels by celecoxib in undifferentiated pheochromocy-
toma (PC12) cells [4] and in A7r5 rat aortic smooth
muscle cells [5], no study has been undertaken in proper
cardiac myocytes. Secondly, unlike the highly consistent
effects of celecoxib on several other ion channels
[5,7,10,11,26], the potency of L-type Ca2+ channel inhib-
ition differed between the two published reports by
nearly 20-fold (IC50s of 0.45 and 8.3 μM) [4,5], which is a
significant difference in the clinical context.
In the human heart, L-type calcium channels (Cav1)
provide an influx of Ca2+ and mediate the excitation–
contraction coupling. Mutations in Cav1.2 can cause the
Timothy syndrome which features congenital heart dis-
ease and may culminate in the sudden death from
arrhythmia [27]. In this work, effects of celecoxib on car-
diac L-type Ca2+ channels were tested in isolated guinea
pig ventricular myocytes using patch-clamp method. Cel-
ecoxib inhibited whole-cell peak L-type Ca2+ currents
Figure 1 Inhibition of KV1.3 channels expressed in CHO cells and LTCCs in guinea pig ventricular myocytes by celecoxib. (A)
Representative examples of KV1.3 currents evoked by 200 ms pulses to +20 mV from a holding potential (HP) of -80 mV in control and after
application of different concentrations of celecoxib (see legend in the panel B); responses of the same cell are shown. (B) Inhibition of LTCCs in
guinea pig ventricular myocytes. Currents were evoked from a HP of -40 mV with a voltage pulse to 0 mV; representative examples of current
traces from the same cell are shown; 1.8 mM Ca2+ was used as a charge carrier. (C) Concentration-dependences for inhibition by celecoxib of
KV1.3 current at the end of 200 ms pulse (n=6) as well as peak LTCC current (n=5); data points were fitted with Hill equation.
Figure 2 Inhibition of L-type Ca2+ channels in Drosophila larval body-wall muscles by celecoxibc. (A) Average LTCC currents in control
evoked by 500 ms pulses to 0 mV from a HP of -40 mV using 10 mM Ba2+ as charge carrier. (B) Average LTCC current in the presence of 100 μM
celecoxib. (C) Effects of 100 μM celecoxib on voltage-dependence of LTCC activation; the dark gray scaled up trace illustrates the depolarizing shift
of activation curve in the presence of 100 μM celecoxib. (D) Voltage-and time-dependence of inhibition; traces were obtained by dividing the
average current traces in the presence of 100 μM celecoxib (panel B) by the average traces in control (panel A); first 5 ms were skipped. (E)
Concentration-dependence for peak LTCC current inhibition by celecoxib at 0 mV; number of experiments for each concentration varied
from 3 to 7.
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to that obtained in A7r5 cells [5].
Drosophila larval body-wall muscles are mainly
employed for studies of ion channels and synaptic trans-
mission in the neuromuscular junction [28,29]. Several
ionic currents are found in these muscles: T-type and L-
type Ca2+ currents; two calcium-activated K+ currents;
and three voltage-activated K+ currents including IA
(Shaker), IKS (Shab), and IKF (molecular basis unknown)
[30]. We recorded Ba2+ currents through LTCCs in
Drosophila larval body-wall muscles using the two-
electrode voltage-clamp method.
Figure 2A shows average LTCC currents in control ex-
periments evoked from a holding potential of-40 mV by
voltage steps from-60 to 40 mV in 10 mV increments.
Celecoxib inhibited Drosophila LTCCs in concentration-
and voltage-dependent manner (Figure 2B-E). Figure 2C
demonstrates the effect of celecoxib on the half-activation
potential (Va½) of LTCCs. V
a
½ was -20.3 ± 0.5 mV (n=21) in
control but -10.3 ± 1.3 mV (n=6) in the presence of
100 μM celecoxib (P < 0.001). Moreover, it follows from
Figure 2D that celecoxib disproportionally reduced peak
LTCC currents and that the inhibition increased during
first several milliseconds after the onset of depolarization.
These results are not consistent with the open-channel
block, which is usually associated with increase in inacti-
vation and a hyperpolarizing shift in the Va½ value, nor
with closed-channel block, which is usually strongest at
the beginning of a depolarizing pulse and gets gradually
relieved during depolarization [13]. In contrast to the
guinea pig, celecoxib inhibited Drosophila LTCCs with
relatively low affinity (an IC50 of 76.0 μM, Figure 2E).
These results imply a substantial variability in celecox-
ib’s action on Ca2+ channels in different experimental
systems. It is not known whether such variability stems
from differences in the expressed channel isoforms
(alpha-1 subunit of Drosophila voltage-dependent Ca2+
channel type D expressed in larval body-wall muscles
[31] and alpha-1C subunit of guinea pig cardiac Ca2+
channel [32] are only 62% identical when the proteins
are aligned using BLAST), or from dissimilar mecha-
nisms of drug action. However, it seems to be unlikely
that differences in recording techniques per se could
contribute to the observed difference in celecoxib po-
tency. For instance, celecoxib inhibits KV2 channels in
the same Drosophila larval body-wall muscle preparation
and in mammalian cell lines with very similar IC50s [13].
Moreover, effects of celecoxib on LTCCs do not depend
on a particular charge carrier [5] even though using
barium abolishes rapid calcium-dependent inactivation
of LTCCs [15].
Although celecoxib potency differences reported here
are likely to originate from molecular dissimilarities be-
tween the guinea pig and Drosophila L-type Ca2+channels, this can hardly be the case for celecoxib effects
on LTCCs in rat PC12 and A7r5 cells [4,5]. The LTCC
IC50 discrepancies between rat PC12 and A7r5 cells
imply that the open channel block is an unlikely mech-
anism of drug action, because the ability of a drug mol-
ecule to bind to its site in the channel pore and
mechanically block the ion flow should not be affected
that drastically by presumably dissimilar channel milieus
in different cell types. Rather, these observations favor
the gating modification mechanism previously described
for celecoxib’s interaction with some other channels
[26]. Biophysical properties of calcium channels are reg-
ulated by factors such as auxiliary subunits, which can
be differentially expressed in different cell types [33] and
thus the extent of channel modulation by celecoxib can
be affected by tissue-specific modification of channel
kinetics by these or other factors.
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